Sepsis Diagnostics Market - Forecast(2024 - 2030)

Sepsis Diagnostics Market Overview

The Sepsis Diagnostics Market size is estimated to reach $477.3 million by 2027 and is poised to grow at a CAGR of 6.4% over the forecast period of 2022-2207. Sepsis is a medical condition or an inflammatory immune response that is caused when the chemicals present in the bloodstream trigger an overwhelming response throughout the body. Moreover, sepsis has the capability to cause a cascade of damages ranging from organ damage to organ failure to ultimate death. Additionally, as per CDC, an infection most often start within one’s lung, urinary tract, skin, or even gastrointestinal tract. Bacterial infections have been identified as the key cause of developing sepsis. However, other viral infections can also induce sepsis. The existing technology present in the market using immunoassay was taking up to 72 hours to provide results. However, the demand for PoC tracings can help to reduce the time to only three or four minutes. Moreover, biological markers are extensively used across as an indicator for pathogen processes and to counter other pharmacological responses. Further, hospital-acquired infections can trigger sepsis in the geriatric population, new-born, or even people suffering from other cardiovascular ailments. The increase in the prevalence of chronic illnesses supplemented by geriatric age along with technologically advanced diagnostics products is identified as the key factor driving the Sepsis Diagnostics Industry Forward in the projected period of 2022-2027.

Report Coverage

The report: “Sepsis Diagnostics Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments of the Sepsis Diagnostics Market.

By Product – Instruments, Blood Culture Media, Assay Kits and Reagents, and Software
By Technology- Microbiology, Molecular Diagnostics, Immunoassays, and Flow Cytometry. 
By Pathogen – Bacterial Sepsis, Virus Sepsis, Fungal Sepsis, and Others.
By Testing Type- Laboratory Testing and Point of Care Testing.
By Severity- Sepsis, Severe Sepsis, and Septic Shock.
By Geography- North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Rest of the World (the Middle East, and Africa).

Key Takeaways

• Geographically, North America’s sepsis diagnostics market held a dominant market share in the year 2021. It is owing to the local presence of major manufacturers/solution providers for sepsis diagnostics; additionally, the region has supportive reimbursement policies which have augmented the growth. However, Asia-Pacific is set to grow at a lucrative pace owing to an increased governmental initiative and the prevalence of chronic illnesses.
• The technological improvements within the diagnostics solutions have been identified as a key driver for the market. However, owing to low knowledge pertaining to the new technologies, the market has faced challenges.
• A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the sepsis diagnostics market report.

Sepsis Diagnostics Market- Geography (%) for 2021.

For More Details on This Report - Request for Sample

Sepsis Diagnostics Market Segmentation Analysis- By Pathogen

The sepsis diagnostics market based on pathogens can be further segmented into Bacterial Sepsis, Virus Sepsis, Fungal Sepsis, and Others. Virus sepsis held a dominant market share in the year 2021. It is owing to the predominant presence of COVID-19 or Sars-Cov-19 virus. Moreover, as per the studies, around 10.4% of people having COVID-19 had an absolute chance of developing severe sepsis. Additionally, the caseload as of 30th October 2021 was 250 million, and the deaths were close to 5 million.

However, the bacterial sepsis segment is estimated to be the fastest-growing, with a CAGR of 7.1% over the forecast period of 2022-2027. It is owing to the predominant position of bacterial sepsis before the pandemic struck, and as per CDC, the major attribute to sepsis has always been bacteria. The bacteria can be further subjugated into gram-positive bacteria and gram-negative bacteria. Moreover, gram-negative sepsis bacteria have been growing in the last decade or two. The gram-negative bacteria do not contain lipopolysaccharide.

Sepsis Diagnostics Market Segmentation Analysis- By Testing Type

The sepsis diagnostics based on testing type can be further segmented into Laboratory Testing and Point of Care Testing. The laboratory testing held a dominant market share in the year 2021. It is owing to more accurate results being provided by the following type. Additionally, it provides one with an in-depth analysis of pathogen and its drug resistance profile. Additionally, the majority of health practitioners use laboratory tests because of their accuracy. Lastly, tests like CRP were predominantly recommended in the pandemic year as it depicted the body’s inflammation levels and also as a biomarker for sepsis.

However, PoC or point of care testing is estimated to be the fastest-growing, with a CAGR of 7.3% over the forecast period of 2022-2027. It is owing to the technological advancement happening within this sub-segment. For example, Thermo Fisher Scientific launched its B·R·A·H·M·S PCT, which allowed for the diagnosis of bacterial infections and sepsis. Moreover, owing to better facilitation, the government is supporting investments to develop such PoC tests as it allows SERO surveys which in turn helps in framing policies and other allotments.

Sepsis Diagnostics Market Segmentation Analysis- By Geography

The Sepsis Diagnostics Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America’s sepsis diagnostics market held a dominant market share of 35% as compared to other regions. Moreover, one in three deaths because of COVID was caused due to sepsis. Additionally, 1.7 million adults in the USA develop sepsis each year. CDC launched the ‘Get Ahead of Sepsis,’ which is an educational initiative to protect the Americans.

However, Asia Pacific is set to offer lucrative growth opportunities to marketers in the projected period of 2022-2027. It is owing to all the disease-causing factors such as diabetes, cancer, and geriatric population, which are rising. According to the OECD, eleven countries would be termed as an aging society by 2040. Moreover, the fertility rates have dipped down, thereby increasing the geriatric population. Lastly, diabetes in the countries like India is expected to have a caseload of 77 million by 2021. Additionally, the obesity indexes of other countries will allow for the growth of diabetes/ cancer and other causes of sepsis.

Sepsis Diagnostics Market Drivers

An increase in the cases of chronic illnesses supplemented by the geriatric population has acted in favor of growth for sepsis diagnostics

As per CDC, people who are older than 65 or have chronic medical conditions such as diabetes, cancer, or any other kidney ailment have a higher risk of acquiring sepsis. Moreover, as per the US CDC, the population curve is drastically shifting towards the senior group. As by their estimations, in the year 2034- the population below 18 and above 65 will break even. And moving ahead, the demographic will favor the older population. Additionally, the cases of chronic illnesses have been on the rise. As per WHO, the number of diabetic populations has quadrupled in the last four decades. Additionally, they estimated that a sedentary lifestyle and globalization would only increase the diabetic population. Similarly, cancer has been identified to be a global killer, and its numbers are supposedly rising owing to various additives and other lifestyle-related habits. The following factors would help in allowing the growth of the sepsis diagnostics market.

An increase in the pace of regulatory approvals supplemented by key innovations has acted as a driver for the market

In the forecast period, product innovations and regulatory approvals are some of the predominant factors which would allow for the growth of the market. For example, a new DxH 690T analyzer launched by Beckman Coulter acted as an early sepsis indicator. Moreover, the University of Strathclyde launched a ground-breaking technology that allowed for the detection of sepsis within three minutes. The listed technology made use of microelectrode, which analyzed patients’ blood samples. Lastly, US FDA has been agile in allowing for the clinical trials and acceptance or launch of new products, which have readily allowed for the growth of the market.

Sepsis Diagnostics Market Challenges

The use of “diagnosis” in sepsis has been a major market challenge

The plausible diagnosis of sepsis has been attributed to the clinical onset of symptoms. For example, fever and chills have been the most common symptom. However, immunosuppressed patients won’t exhibit the same symptoms. Hence, it becomes a challenge to identify the need to perform diagnostic tests. Additionally, there have been around 170 clinically approved biomarkers that would allow diagnosis for sepsis, but none of the recognized have been attributed as 100% specific for sepsis. For example, CRP has been a predominant biomarker, but its sensitivity is not only to the presence of sepsis-causing ailment. Additionally, PCT has been another bio-marker, but it also latches on the presence of other inflammatory conditions. Hence, owing to various complexities, the sepsis diagnostic market has faced challenges in growth.

Sepsis Diagnostics Market Competitive Landscape

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Sepsis Diagnostics Market. The top 10- Sepsis Diagnostics Market companies include:

1. Abbott
2. Becton, Dickinson, and Company
3. BioMérieux SA
4. Bruker Corporation
5. F. Hoffmann-LA Roche Ltd
6. Immunexpress Inc
7. Luminex Corporation
8. Response Biomedical Corp
9. T2 Biosystems, Inc
10. Thermo Fisher Scientific

Recent Developments

• In December 2020, A new blood test "PERSEVERE" was launched which assesses five markers in the blood to predict who is at low/medium/high risk of death by Sepsis. The five biomarkers are -> CCL3 or Chemokine Ligand; Interleukin 8 or IL8; HSPA1B or Heat Shock Protein; Granzyme B (GZMB), and lastly MMP8 or metallopeptidase 8. 
• In November 2020, Immunexpress launched SeptiCyte RAPID. The technology would allow leveraging the host-response gene expression biomarkers to determine the chances of sepsis. The product is also capable of identifying fungal infections and can also be used to identify the sepsis-causing pathogen such as bacterial, fungal, and viral pathogens. The test can provide results within one hour and will aid the clinicians in diagnosing sepsis.
• In April 2020, Cytovale received additional funding from BARDA to evaluate its Sepsis Diagnostics in PUI for COVID-19 afflicted patients. The product has the capacity to provide results in ten minutes, and the study will be conducted in partnership with Louisiana State University and Lady of the Lake Regional Medical Center in Baton Rouge, LA. The trial included 600 patients.

Relevant Titles

Diagnostics ECG Market- Forecast (2022-2027)

Report Code- HCR 0063

Diagnostic Imaging Services Market- Forecast (2022-2027)

Report Code- HCR 0248 

For more Lifesciences and Healthcare Market reports, please click here